• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12G filed by 2seventy bio Inc.

    5/23/25 4:14:52 PM ET
    $TSVT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TSVT alert in real time by email
    15-12G 1 ef20049536_1512g.htm 15-12G
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    FORM 15



    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
    UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
    OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
    OF THE SECURITIES EXCHANGE ACT OF 1934.

    Commission File Number: 001-40791



    2seventy bio, Inc.
    (Exact name of registrant as specified in its charter)



    60 Binney Street
    Cambridge, Massachusetts, 02142
    (617) 675-7270
    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    Common Stock, par value $0.0001 per share
    (Title of each class of securities covered by this Form)

    None
    (Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)



    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

    Rule 12g-4(a)(1)
    ☒
    Rule 12g-4(a)(2)
    ☐
    Rule 12h-3(b)(1)(i)
    ☒
    Rule 12h-3(b)(1)(ii)
    ☐
    Rule 15d-6
    ☐
    Rule 15d-22(b)
    ☐

    Approximate number of holders of record as of the certification or notice date: One (1) holder.



    Pursuant to the requirements of the Securities Exchange Act of 1934, 2seventy bio, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     
    2seventy bio, Inc.
       
     
    By:
    /s/ Amy Fallone
     
    Name:
    Amy Fallone
     
    Title:
    Vice President and Secretary
         
     Date: May 23, 2025    



    Get the next $TSVT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TSVT

    DatePrice TargetRatingAnalyst
    6/6/2024$5.00 → $2.00Neutral → Sell
    Goldman
    1/31/2024Outperform → Market Perform
    TD Cowen
    1/31/2024$5.00 → $18.00Market Perform → Outperform
    Leerink Partners
    10/30/2023$6.00Outperform → Market Perform
    Leerink Partners
    10/12/2023$13.00Buy
    Citigroup
    9/13/2023$5.00Buy → Neutral
    Goldman
    9/12/2023Buy → Neutral
    Guggenheim
    7/28/2023$25.00 → $13.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $TSVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Glickman Sarah Js returned 12,050 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - 2seventy bio, Inc. (0001860782) (Issuer)

      5/15/25 8:53:38 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Casdin Capital, Llc

      4 - 2seventy bio, Inc. (0001860782) (Issuer)

      5/15/25 4:51:03 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Leschly Nick returned 335,964 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - 2seventy bio, Inc. (0001860782) (Issuer)

      5/15/25 4:35:59 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TSVT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb

      Acquisition by Bristol Myers Squibb on track to close in the second quarter of 2025: HSR waiting period expired on May 2, 2025; tender offer expected to expire on May 13, 2025 Abecma generated $59 million U.S. commercial revenue in the first quarter of 2025 Ended quarter with approximately $173 million in cash, cash equivalents, and marketable securities 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the first quarter ended March 31, 2025. "We started 2seventy with a singular focus on harnessing the power of cell therapy to deliver more time for people living with cancer," said Chip Baird, chief executive officer, 2seventy bio. "Over the pas

      5/7/25 4:05:00 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results

      Entered into definitive merger agreement to be acquired by Bristol Myers Squibb at a price of $5.00 per share in an all-cash transaction; expected to close in the second quarter of 2025 Abecma generated $242 million U.S. sales in 2024 79% reduction in year-over-year net cash spend reflects continued streamlining of cost structure Ended 2024 with approximately $184 million in cash, cash equivalents, and marketable securities 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2024. "2024 was a pivotal year for 2seventy as we made significant changes to our business to streamline cost structure a

      3/25/25 4:05:00 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

      $5.00 per share, all-cash transaction Expected to close in the second quarter of 2025, subject to customary closing conditions 2seventy bio, Inc. (NASDAQ:TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE:BMY) ("BMS") will acquire all of the outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash transaction for a total equity value of approximately $286 million, or $102 million net of estimated cash. The deal represents an 88% premium to the closing price of $2.66 on March 7, 2025. "A year ago, 2seventy decided to exclusively focus on unlocking the value of Abecma, with the goal of delivering more time for people living wi

      3/10/25 10:17:00 PM ET
      $BMY
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care